Radiopharm Theranostics (ASX:RAD) EV-to-EBIT : -0.30 (As of May. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Radiopharm Theranostics's Enterprise Value is A$14.22 Mil. Radiopharm Theranostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-47.17 Mil. Therefore, Radiopharm Theranostics's EV-to-EBIT for today is -0.30.

The historical rank and industry rank for Radiopharm Theranostics's EV-to-EBIT or its related term are showing as below:

ASX:RAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.77 Med: 0 Max: 1.08
Current: -0.31

During the past 2 years, the highest EV-to-EBIT of Radiopharm Theranostics was 1.08. The lowest was -0.77. And the median was 0.00.

ASX:RAD's EV-to-EBIT is ranked worse than
100% of 423 companies
in the Biotechnology industry
Industry Median: 10.05 vs ASX:RAD: -0.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Radiopharm Theranostics's Enterprise Value for the quarter that ended in Dec. 2023 was A$24.23 Mil. Radiopharm Theranostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-47.17 Mil. Radiopharm Theranostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -194.67%.

Radiopharm Theranostics EV-to-EBIT Historical Data

The historical data trend for Radiopharm Theranostics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics EV-to-EBIT Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

EV-to-EBIT

-0.72

-0.84

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	-	-	-	-	-

Competitive Comparison of Radiopharm Theranostics's EV-to-EBIT

For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's EV-to-EBIT falls into.

Radiopharm Theranostics EV-to-EBIT Calculation

Radiopharm Theranostics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	14.219	/	-47.165
	=	-0.30

Radiopharm Theranostics's current Enterprise Value is A$14.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-47.17 Mil.

Radiopharm Theranostics (ASX:RAD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Radiopharm Theranostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-47.165	/	24.22873
	=	-194.67 %

Radiopharm Theranostics's Enterprise Value for the quarter that ended in Dec. 2023 was A$24.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-47.17 Mil.

Radiopharm Theranostics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (ASX:RAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

RDPTF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines